DPP-4 inhibitors × body weight & composition

TrialDiabetes care2025

Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial.

Deborah J Wexler et al.PubMed ↗Full text ↗Publisher ↗

  • Liraglutidelooks good hereLower weight change during the first year.Randomised, large.
  • Sitagliptinlooks good hereLower weight change during the first year.Randomised, large.
  • Glarginelooks bad hereHigher weight change during the first year.Randomised, large.
  • Glimepiridelooks bad hereHigher weight change during the first year.Randomised, large.

What the trial testedrandomised · 4,980 people · 2025

Randomised comparison

Lowered weight change during the first year

−3.50−3.80 to −3.20

liraglutide

As reported

difference −3.5, 95% CI −3.80 to −3.20

Randomised comparison

Lowered weight change during the first year

−1.07−1.40 to −0.78

sitagliptin

As reported

difference −1.07, 95% CI −1.40 to −0.78

Randomised comparison

Raised weight change during the first year

+0.45+0.16 to +0.74

glargine

As reported

difference 0.45, 95% CI 0.16–0.74

Randomised comparison

Raised weight change during the first year

+0.89+0.60 to +1.20

glimepiride

As reported

difference 0.89, 95% CI 0.60–1.20

Who was studied, and how

7,850people in the Glycemia Reduction Approaches in Diabetes trial, from 2013
4,980of them with cardiovascular disease, in this paper

The trial randomly assignedassigned by chance

liraglutide
the rest

Lowered weight change during the first year−3.50

randomised

The trial randomly assignedassigned by chance

sitagliptin
the rest

Lowered weight change during the first year−1.07

randomised

the abstract, start to end

change (kg) during the first year was -3.5 (-3.8,-3.2) with liraglutide,-1.07 (-1.4,-0.78) with sitagliptin, 0.45 (0.16, 0.74) with glargine, and 0.89 (0.60, 1.2) with glimepiride (P

← favours treatmentfavours comparator →
could be chance
Weight change (kg) during the first yearliraglutide
−3.5−3.80 to −3.20
Weight change (kg) during the first yearsitagliptin
−1.07−1.40 to −0.78
Weight change (kg) during the first yearglargine
0.450.16–0.74
Weight change (kg) during the first yearglimepiride
0.890.60–1.20
GLP-1 receptor agonistsDPP-4 inhibitorsSulfonylureas & glinidesInsulinBody weight & composition
1 / 4

5 papers cite it

2025
2026
this papercites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 40267365